156 related articles for article (PubMed ID: 30478295)
1. Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening.
Zhang J; Shen L; Johnston SA
Sci Rep; 2018 Nov; 8(1):17366. PubMed ID: 30478295
[TBL] [Abstract][Full Text] [Related]
2. Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model.
Peterson M; Murphy SN; Lainson J; Zhang J; Shen L; Diehnelt CW; Johnston SA
BMC Immunol; 2020 May; 21(1):25. PubMed ID: 32370785
[TBL] [Abstract][Full Text] [Related]
3. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
4. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
5. RNA Transcription and Splicing Errors as a Source of Cancer Frameshift Neoantigens for Vaccines.
Shen L; Zhang J; Lee H; Batista MT; Johnston SA
Sci Rep; 2019 Oct; 9(1):14184. PubMed ID: 31578439
[TBL] [Abstract][Full Text] [Related]
6. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
7. Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens.
Shen L; Brown JR; Johnston SA; Altan M; Sykes KF
J Transl Med; 2023 May; 21(1):338. PubMed ID: 37217961
[TBL] [Abstract][Full Text] [Related]
8. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
9. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
10. A Thermosensitive Bi-Adjuvant Hydrogel Triggers Epitope Spreading to Promote the Anti-Tumor Efficacy of Frameshift Neoantigens.
Ke Y; Xin K; Tao Y; Li L; Chen A; Shao J; Zhu J; Zhang D; Cen L; Chu Y; Yu L; Liu B; Liu Q
Adv Sci (Weinh); 2024 Apr; 11(14):e2306889. PubMed ID: 38308098
[TBL] [Abstract][Full Text] [Related]
11. Comparison patterns of 4 T1 antigens recognized by humoral immune response mediated by IgG and IgM antibodies in female and male mice with breast cancer using 2D-immnunoblots.
Díaz-Zaragoza M; Hernández-Ávila R; Govezensky T; Mendoza L; Meneses-Ruíz DM; Ostoa-Saloma P
Immunobiology; 2015 Sep; 220(9):1050-8. PubMed ID: 26026196
[TBL] [Abstract][Full Text] [Related]
12. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability.
Ishikawa T; Fujita T; Suzuki Y; Okabe S; Yuasa Y; Iwai T; Kawakami Y
Cancer Res; 2003 Sep; 63(17):5564-72. PubMed ID: 14500396
[TBL] [Abstract][Full Text] [Related]
13. HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model.
Schrörs B; Lübcke S; Lennerz V; Fatho M; Bicker A; Wölfel C; Derigs P; Hankeln T; Schadendorf D; Paschen A; Wölfel T
Oncotarget; 2017 Apr; 8(17):28312-28327. PubMed ID: 28423700
[TBL] [Abstract][Full Text] [Related]
14. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
[TBL] [Abstract][Full Text] [Related]
15. A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity.
Walters JN; Ferraro B; Duperret EK; Kraynyak KA; Chu J; Saint-Fleur A; Yan J; Levitsky H; Khan AS; Sardesai NY; Weiner DB
Mol Ther; 2017 Apr; 25(4):976-988. PubMed ID: 28237837
[TBL] [Abstract][Full Text] [Related]
16. Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer.
Dehghan-Manshadi M; Nikpoor AR; Hadinedoushan H; Zare F; Sankian M; Fesahat F; Rafatpanah H
Int Immunopharmacol; 2021 Apr; 93():107414. PubMed ID: 33578183
[TBL] [Abstract][Full Text] [Related]
17. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma.
Monzavi-Karbassi B; Hennings LJ; Artaud C; Liu T; Jousheghany F; Pashov A; Murali R; Hutchins LF; Kieber-Emmons T
Vaccine; 2007 Apr; 25(16):3022-31. PubMed ID: 17303294
[TBL] [Abstract][Full Text] [Related]
19. Reactivity against microsatellite instability-induced frameshift mutations in patients with inflammatory bowel disease.
Kuehn F; Klar E; Bliemeister A; Linnebacher M
World J Gastroenterol; 2015 Jan; 21(1):221-8. PubMed ID: 25574094
[TBL] [Abstract][Full Text] [Related]
20. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
